CJC-1295 NO-DAC 2mg (MOD GRF 1-29)

CJC-1295 NO-DAC is a synthetic peptide. It contains an amino acid sequence (the first 29 amino acids) of growth hormone-releasing hormone (GHRH).¹ Since the peptide contains 29 amino acids, it is also known as modified growth releasing factor 1-29 (MOD GFR 1-29).¹ CJC-1295 has a molecular weight of just under 3.4 kDa. Endogenously produced GHRH has 44 amino acids in its chain structure. Because the first 29 amino acids retain all of GHRH's features, CJC-1295 functions exactly like GHRH and can be used for a variety of in vitro experiments studying growth and development.² Due to the lack of drug affinity complex (DAC) treatment, this peptide may promote a more physiological response during in vitro experiments. The Human GRF template (amino acids’ sequence) was used to design different GFR analogs. Modification of original amino acids with their isoforms from other species results in an overall improved peptide.³ For example, replacing the first two amino acids in the mouse sequence inhibits peptidase metabolism, improving cell culture stability.⁴ Half-life of this peptide is about 30 minutes, which is more than the unmodified form of the peptide. It was found that CJC-1295 increases the release of insulin-like growth factor 1 (IGF-1) in animals.³ Furthermore, GNRH knockout mice receiving daily doses of CJC-1295 for 5 weeks showed normal body weight and length comparable to the control group.¹ In addition to this, CJC-1295 is also used to study impaired secretion of GH in a rat model of obesity.⁵ In addition, according to some studies, modGRF has superior pharmacokinetic and pharmacodynamic properties to intrinsic GHRH.⁴ In summary, with the biological effects of CJC-1295 on growth hormone as well as IGF-1 release, it could be used in in vitro experiments studying growth, development, and metabolic disorders like diabetes.

The peptide is provided in a vial as a 2 mg lyophilized powder.